A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Trial Profile

A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2018

At a glance

  • Drugs D 0502 (Primary) ; Palbociclib (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors InventisBio
  • Most Recent Events

    • 20 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 27 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top